SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration

Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration

Overview

Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@wiley2016]

Cellular senescence is a state of irreversible cell cycle arrest that emerges in response to various stresses, including telomere erosion, DNA damage, oncogene activation, and mitochondrial dysfunction [1](https://pubmed.ncbi.nlm.nih.gov/18174374/). While senescence serves as a tumor suppression mechanism, the accumulation of senescent cells over time contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a complex secretome that includes pro-inflammatory cytokines, chemokines, growth factors, proteases, and bioactive lipids [2](https://pubmed.ncbi.nlm.nih.gov/20074542/). In the aging brain, SASP drives chronic neuroinflammation, disrupts neuronal function, and accelerates neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [3](https://pubmed.ncbi.nlm.nih.gov/29429539/). [@dou2017]

Molecular Mechanisms of SASP Induction

DNA Damage Response

Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration

Overview

Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@wiley2016]

Cellular senescence is a state of irreversible cell cycle arrest that emerges in response to various stresses, including telomere erosion, DNA damage, oncogene activation, and mitochondrial dysfunction [1](https://pubmed.ncbi.nlm.nih.gov/18174374/). While senescence serves as a tumor suppression mechanism, the accumulation of senescent cells over time contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a complex secretome that includes pro-inflammatory cytokines, chemokines, growth factors, proteases, and bioactive lipids [2](https://pubmed.ncbi.nlm.nih.gov/20074542/). In the aging brain, SASP drives chronic neuroinflammation, disrupts neuronal function, and accelerates neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [3](https://pubmed.ncbi.nlm.nih.gov/29429539/). [@dou2017]

Molecular Mechanisms of SASP Induction

DNA Damage Response

The primary driver of SASP is the persistent DNA damage response (DDR). When cells experience telomere shortening or genotoxic stress, ATM/ATR kinases phosphorylate downstream effectors including p53, CHK1, and CHK2, leading to cell cycle arrest [4](https://pubmed.ncbi.nlm.nih.gov/14676321/). In neurons and glia, chronic DDR activation—without complete repair—triggers SASP: [@griffin2001]

• p53 activation: Stabilizes p21, perpetuating cell cycle arrest [5](https://pubmed.ncbi.nlm.nih.gov/16873159/)
• p16^INK4a accumulation: Retinoblastoma pathway activation maintains senescence [6](https://pubmed.ncbi.nlm.nih.gov/19011617/)
• γH2AX foci: Persistent DNA damage markers correlate with SASP in aging brain [7](https://pubmed.ncbi.nlm.nih.gov/20453856/)

Mitochondrial Dysfunction

Mitochondrial dysfunction is both a cause and consequence of cellular senescence. Damaged mitochondria produce excess reactive oxygen species (ROS), causing oxidative damage to nuclear and mitochondrial DNA [8](https://pubmed.ncbi.nlm.nih.gov/18692778/). Key connections include: [@glaser2003]

• mitochondrial DNA damage: Triggers SASP via cytosolic DNA sensing (cGAS-STING) [9](https://pubmed.ncbi.nlm.nih.gov/26416427/)
• NAD+ depletion: Mitochondrial dysfunction reduces NAD+ levels, impairing sirtuin activity and DNA repair [10](https://pubmed.ncbi.nlm.nih.gov/23335367/)
• mitokine signaling: Mitochondrial dysfunction releases factors that promote systemic inflammation [11](https://pubmed.ncbi.nlm.nih.gov/23254930/)

cGAS-STING Pathway

The cGAS-STING cytosolic DNA sensing pathway is a critical activator of SASP in senescent cells. When DNA accumulates in the cytosol (from nuclear envelope breakdown, mitochondrial DNA release, or foreign DNA), cGAS catalyzes cGAMP production, which activates STING and downstream TBK1-IRF3 signaling [12](https://pubmed.ncbi.nlm.nih.gov/26436954/). This pathway: [@ber2001]

• Induces type I interferon response
• Activates NF-κB, driving pro-inflammatory cytokine transcription
• Maintains the senescent growth arrest

SASP Components and Their Neurotoxic Effects

Pro-Inflammatory Cytokines

| Cytokine | Function | Neurodegenerative Relevance | [@mcalpine2011]
|----------|----------|----------------------------| [@ishizuka2008]
| IL-1β | Pro-inflammatory, activates microglia | Drives chronic neuroinflammation in AD [13](https://pubmed.ncbi.nlm.nih.gov/11929557/) | [@semple2010]
| IL-6 | Acute phase response, B cell maturation | Elevated in AD/PD CSF [14](https://pubmed.ncbi.nlm.nih.gov/16876378/) | [@tran2008]
| IL-8 | Chemoattractant for neutrophils | Attracts peripheral immune cells to brain [15](https://pubmed.ncbi.nlm.nih.gov/10881951/) | [@flanders2003]
| TNF-α | Master inflammatory regulator | Synaptic dysfunction in AD [16](https://pubmed.ncbi.nlm.nih.gov/19536264/) | [@tarkowski2006]

Chemokines

• CCL2 (MCP-1): Recruits monocytes; elevated in AD and PD brain [17](https://pubmed.ncbi.nlm.nih.gov/18614020/)
• CXCL1, CXCL8: Neutrophil chemoattractants; implicated in neuroinflammation [18](https://pubmed.ncbi.nlm.nih.gov/19428734/)
• CXCL12 (SDF-1): Regulates neural progenitor cell migration; altered in AD [19](https://pubmed.ncbi.nlm.nih.gov/18493597/)

Growth Factors and Proteases

• TGF-β: Paradoxical effects—both pro- and anti-inflammatory [20](https://pubmed.ncbi.nlm.nih.gov/12551936/)
• VEGF: Angiogenesis factor; implicated in AD vascular changes [21](https://pubmed.ncbi.nlm.nih.gov/16988479/)
• MMP-1, MMP-3, MMP-9: Extracellular matrix degradation; disrupt blood-brain barrier [22](https://pubmed.ncbi.nlm.nih.gov/14690346/)
• PAI-1: Plasminogen inhibitor; elevated in aging and AD [23](https://pubmed.ncbi.nlm.nih.gov/12468322/)

SASP in Alzheimer's Disease

Neuronal Senescence

Surprisingly, post-mitotic neurons can enter a senescent-like state characterized by: [@lee2003]

• Loss of synaptic proteins: Synapsin I, PSD-95 downregulation [24](https://pubmed.ncbi.nlm.nih.gov/25446704/)
• Tau hyperphosphorylation: p16^INK4a-mediated cell cycle re-entry attempts [25](https://pubmed.ncbi.nlm.nih.gov/25910975/)
• Metabolic dysfunction: Reduced mitochondrial respiration [26](https://pubmed.ncbi.nlm.nih.gov/26234213/)

Microglial SASP

Microglia adopt SASP in the aging brain, contributing to chronic neuroinflammation: [@bohren2004]

• NLRP3 inflammasome activation: IL-1β release in response to Aβ [27](https://pubmed.ncbi.nlm.nih.gov/26431797/)
• Complement activation: C1q tagging of synapses for elimination [28](https://pubmed.ncbi.nlm.nih.gov/26283459/)
• TREM2 variants: Risk for late-onset AD affect microglial senescence [29](https://pubmed.ncbi.nlm.nih.gov/27059855/)

Aβ-SASP Feedback Loop

Aβ and SASP create a vicious cycle: [@jurk2012]

SASP in Parkinson's Disease

Dopaminergic Neuron Senescence

The substantia nigra pars compacta (SNc) dopaminergic neurons are particularly vulnerable to senescence: [@mohammad2015]

• High metabolic demand: Mitochondrial dysfunction triggers premature senescence [30](https://pubmed.ncbi.nlm.nih.gov/24769860/)
• Neuromelanin accumulation: Acts as a pro-senescent signal [31](https://pubmed.ncbi.nlm.nih.gov/20811342/)
• α-Synuclein aggregation: Induces DNA damage response [32](https://pubmed.ncbi.nlm.nih.gov/25943841/)

Glial SASP

Astrocytes and microglia in PD brain show SASP-like states: [@wiley2015]

• Reactive astrocytes: Secrete CCL2, IL-6, CXCL8 [33](https://pubmed.ncbi.nlm.nih.gov/22986138/)
• SASP in astrocytes: Promotes α-synuclein propagation [34](https://pubmed.ncbi.nlm.nih.gov/25632092/)

Therapeutic Strategies

Senolytics

| Drug | Target | Status | [@heneka2015]
|------|--------|--------| [@stevens2015]
| Dasatinib + Quercetin | Pan-tyrosine kinase + senolytic | Clinical trials [35](https://pubmed.ncbi.nlm.nih.gov/31740805/) | [@ulrich2016]
| Navitoclax (ABT-263) | Bcl-2 family | Preclinical [36](https://pubmed.ncbi.nlm.nih.gov/25417114/) | [@ryan2013]
| Fisetin | mTOR, senolytic | Preclinical [37](https://pubmed.ncbi.nlm.nih.gov/27453471/) | [@zecca2008]
| Metformin | AMPK, reduces SASP | Clinical trials [38](https://pubmed.ncbi.nlm.nih.gov/26615402/) | [@schiapparelli2015]

SASP Modulators

• Rapamycin: mTOR inhibition reduces SASP [39](https://pubmed.ncbi.nlm.nih.gov/20153622/)
• JAK inhibitors: Block IL-6/STAT3 signaling [40](https://pubmed.ncbi.nlm.nih.gov/20818891/)
• NF-κB inhibitors: Prevent SASP transcription [41](https://pubmed.ncbi.nlm.nih.gov/18688284/)
• Aspirin: Anti-inflammatory; reduces SASP in vitro [42](https://pubmed.ncbi.nlm.nih.gov/20847057/)

Biomarkers

Peripheral Markers

• IL-6: Elevated in plasma of AD and PD patients [43](https://pubmed.ncbi.nlm.nih.gov/16876378/)
• CXCL12: Increased in aging; associated with cognitive decline [44](https://pubmed.ncbi.nlm.nih.gov/23251661/)
• PAI-1: Predicts incident dementia [45](https://pubmed.ncbi.nlm.nih.gov/21832241/)

CSF Markers

• IL-1β: Elevated in AD CSF [46](https://pubmed.ncbi.nlm.nih.gov/14690346/)
• TGF-β: Reduced in PD CSF [47](https://pubmed.ncbi.nlm.nih.gov/21885724/)

Conclusion

SASP represents a critical link between aging, cellular senescence, and neurodegenerative disease. The chronic inflammatory state induced by SASP creates a permissive environment for protein aggregation, synaptic dysfunction, and neuronal death. Therapeutic strategies targeting senescent cells or SASP components offer promising avenues for disease modification. [@brouillette2013]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration discovered through SciDEX knowledge graph analysis: